Critical Care
RCT: Immediate oral refeeding in patients with mild and moderate acute pancreatitis.
22 Jul, 2021 | 10:32h | UTCImmediate Oral Refeeding in Patients With Mild and Moderate Acute Pancreatitis: A Multicenter, Randomized Controlled Trial (PADI trial) – Annals of Surgery (link to abstract – $ for full-text)
A Narrative Review on the Role of Staphylococcus aureus Bacteriuria in S. aureus Bacteremia.
22 Jul, 2021 | 10:37h | UTC
Commentary on Twitter
✨If you have Staph in urine check blood culture✨
💥Excellent narrative review on the role of Staphylococcus aureus Bacteriuria in S. aureus Bacteremia
Epidemiology and pathogenesis of SABU in patients with SAB💥 #IDTwitter #ofid https://t.co/wioI3I528z pic.twitter.com/54jVQEBeDW— Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 (@ABsteward) March 30, 2021
Expert review | Postpartum preeclampsia or eclampsia: defining its place and management among the hypertensive disorders of pregnancy.
21 Jul, 2021 | 10:37h | UTC
Commentary on Twitter
AJOG Expert Review in Preeclampsia: Postpartum preeclampsia or eclampsia: defining its place and management among the hypertensive disorders of pregnancy https://t.co/xdZbn51ymU pic.twitter.com/N90GdbdBBw
— AJOG (@AJOG_thegray) July 20, 2021
Cohort study: Sickle cell disorders and severe COVID-19 outcomes – “Our analysis estimated a 4-fold increased risk for COVID-19–related hospitalization and a 2.6-fold increased risk for COVID-19–related death for sickle cell disease”.
21 Jul, 2021 | 10:44h | UTCSickle Cell Disorders and Severe COVID-19 Outcomes: A Cohort Study – Annals of Internal Medicine
ICU Survivorship—The relationship of delirium, sedation, dementia, and acquired weakness.
21 Jul, 2021 | 10:32h | UTC
WHO Guidance for clinical case management of thrombosis with thrombocytopenia syndrome (TTS) following vaccination to prevent coronavirus disease (COVID-19).
20 Jul, 2021 | 10:29h | UTCRelated Guidance: AHA/ASA Guidance: Diagnosis and Management of Cerebral Venous Sinus Thrombosis with Vaccine-Induced Thrombotic Thrombocytopenia – “No heparin products in any dose should be given.” AND ISTH Interim Guidance for the Diagnosis and Treatment on Vaccine Induced Immune Thrombotic Thrombocytopenia
International Registry: Ischemic and hemorrhagic stroke among critically ill patients with Covid-19.
20 Jul, 2021 | 10:21h | UTCRelated: SARS-CoV-2 and Stroke Characteristics – higher rate of large vessel occlusions and stroke in young patients AND Case series of 18 male adults aged 50 years or younger with acute ischemic stroke during the convalescent phase of asymptomatic Covid-19 AND Case-control study: COVID-19-associated stroke is associated with worse outcomes and increased mortality AND Pictorial essay: Neurological emergencies associated with COVID-19: stroke and beyond AND Characteristics and Outcomes in Patients With COVID-19 and Acute Ischemic Stroke AND Risk of Ischemic Stroke in Patients with COVID-19 vs. Patients with Influenza
WHO warns that HIV infection increases risk of severe and critical COVID-19.
20 Jul, 2021 | 10:24h | UTCNews release: WHO warns that HIV infection increases risk of severe and critical COVID-19 – World Health Organization
Commentary on Twitter (thread – click for more)
🆕 report confirms that #HIV infection is a significant independent risk factor for both severe/critical #COVID19 presentation at hospital admission & in-hospital mortality. 23.1% of all people living with HIV who were hospitalized with COVID-19, died.
👉 https://t.co/UBd0OyFKnd pic.twitter.com/UHLo9RPa1g
— World Health Organization (WHO) (@WHO) July 16, 2021
RCT: more data showing Azithromycin is not better than placebo in patients with Covid-19.
18 Jul, 2021 | 23:54h | UTCRelated: RCT: Another study shows Azithromycin does not improve outcomes in patients with Covid-19. (several articles on the subject)
Commentary on Twitter
Among outpatients with #SARSCoV2 infection, treatment with a single dose of oral #azithromycin compared with placebo did not result in a greater likelihood of being free of symptoms at day 14 https://t.co/dYDcSyGtwd #COVID19
— JAMA (@JAMA_current) July 16, 2021
Review: Acute kidney injury.
18 Jul, 2021 | 23:18h | UTCAcute kidney injury – Nature Reviews Disease Primers (free for a limited period)
Commentary on Twitter
Get Primed on #AcuteKidneyInjury with our NEW PrimeView, FREE to download this week https://t.co/4RAOOaB8ep pic.twitter.com/d5iHCcqJwY
— Nature Reviews Disease Primers (@DiseasePrimers) July 15, 2021
Short review: The gut in COVID-19.
16 Jul, 2021 | 10:54h | UTCThe gut in COVID-19 – Intensive Care Medicine
Commentary on Twitter
Gut & #COVID19, main findings
➡️clinical GI features
➡️pathophysiology: cytotoxic enterocyte injury, microvascular injury/thromboinfammation, non‑specifc critical illness‑related dysfunction
➡️GI dysfunction in severe #SARSCoV2 vs other critical illnesseshttps://t.co/wzzTNldInN pic.twitter.com/DnHLMsSu6v— Intensive Care Medicine (@yourICM) July 9, 2021
Pathophysiology of COVID-19-associated acute kidney injury.
16 Jul, 2021 | 10:52h | UTCPathophysiology of COVID-19-associated acute kidney injury – Nature Reviews Nephrology
M-A of randomized trials: In patients with acute respiratory distress syndrome, there was no difference in mortality between higher vs. lower positive end-expiratory pressure strategies.
16 Jul, 2021 | 10:43h | UTC
Review: Sedation in the Intensive Care Unit.
16 Jul, 2021 | 10:31h | UTCSedation in the Intensive Care Unit – Current Anesthesiology Reports
M-A: Utility of intravenous Alteplase prior to endovascular stroke treatment.
15 Jul, 2021 | 09:03h | UTCUtility of Intravenous Alteplase Prior to Endovascular Stroke Treatment: A Systematic Review and Meta-analysis of RCTs – Neurology (link to abstract – $ for full-text)
Commentary: Direct thrombectomy, bridging therapy confer similar functional outcomes in stroke – Healio (free registration required)
Commentary on Twitter
Via @GreenJournal: For #patients with acute large vessel occlusion, functional outcomes were similar for those receiving direct #endovascular treatment and bridging therapy.#NeuroTwitter #neurology https://t.co/LweNGwOhVB pic.twitter.com/jqgZyV9ZOA
— Neurology Today (@NeurologyToday) June 22, 2021
RCT: Lopinavir-ritonavir and hydroxychloroquine worsened outcomes in critically ill patients with COVID-19.
14 Jul, 2021 | 11:25h | UTC
Commentary on Twitter (thread – click for more)
Results of @remap_cap #Covid_19 #Antiviral Domain released Online First @yourICM: Among critically ill patients with COVID-19, #lopinavir-ritonavir, #HydroxyChloroquine, or combination therapy worsened outcomes compared to no antiviral therapy
— remap-cap (@remap_cap) July 13, 2021
RCT: Neither Remdesivir nor Hydroxychloroquine affect viral clearance in hospitalized patients with COVID-19.
14 Jul, 2021 | 11:23h | UTCNews release: Neither remdesivir nor HCQ affect viral clearance in hospitalized patients with COVID-19 – American College of Physicians
Original Study: Evaluation of the Effects of Remdesivir and Hydroxychloroquine on Viral Clearance in COVID-19 – Annals of Internal Medicine
Commentary on Twitter
Newly published research in Annals concludes neither remdesivir nor #hydroxychloroquine affected viral clearance in hospitalized patients with #COVID19 https://t.co/K3qWLUW8uY. pic.twitter.com/ugbjJJ3qI5
— Annals of Int Med (@AnnalsofIM) July 12, 2021
FDA Safety Alert: hydroxyethyl starch products should not be used unless adequate alternative treatment is unavailable.
14 Jul, 2021 | 10:48h | UTCCommentary: FDA Piles on New Warnings for Blood Volume Expanders – MedPage Today (free registration required)
Related: Hydroxyethyl-starch Solutions (HES) Should no Longer be Used – European Medicines Agency AND Randomized Trial: Hydroxyethyl Starch vs. Saline for Volume Replacement Therapy in High-Risk Patients Undergoing Major Abdominal Surgery AND Systematic Review: Colloids vs Crystalloids for Fluid Resuscitation in Critically Ill People
German national treatment guidance for hospitalized COVID-19 patients.
13 Jul, 2021 | 10:02h | UTC
Extremely rare cases of Guillain-Barré reported with Johnson & Johnson vaccine for Covid-19.
13 Jul, 2021 | 09:48h | UTCJ&J’s Covid-19 vaccine may trigger neurological condition in rare cases, FDA says – STAT
See also: Johnson & Johnson Vaccine Is Linked To Neurological Disorder In Extremely Rare Cases – NPR AND F.D.A. Attaches Warning of Rare Nerve Syndrome to Johnson & Johnson Vaccine – The New York Times
M-A: Similar mortality with Fluoroquinolones or Macrolides for the treatment of Legionella Pneumonia.
13 Jul, 2021 | 09:18h | UTCAre Fluoroquinolones or Macrolides Better for Treating Legionella Pneumonia? A Systematic Review and Meta-analysis – Clinical Infectious Diseases (link to abstract – $ for full-text)
Review: Infectious disease-associated encephalopathies.
13 Jul, 2021 | 09:30h | UTCInfectious disease-associated encephalopathies – Critical Care
Commentary on Twitter
A Review published in Critical Care focuses on the pathophysiology of encephalopathies associated with sepsis, malaria, influenza, and COVID-19; emerging therapeutic strategies; and the role of neuroinflammation. https://t.co/991S4kAKJk
— BMC (@BioMedCentral) July 11, 2021
Top 10 pearls for the recognition, evaluation, and management of maternal sepsis.
13 Jul, 2021 | 09:25h | UTC
[Preprint] Heparin for Moderately Ill Patients with Covid-19 – “In moderately ill ward patients with Covid-19 and elevated D-dimer level, therapeutic heparin did not significantly reduce the primary outcome but decreased the odds of death at 28 days”.
12 Jul, 2021 | 03:14h | UTCHeparin for Moderately Ill Patients with Covid-19 – medRxiv
Related: RCT: In patients hospitalized with Covid-19 with elevated D-Dimer, a full-dose anticoagulation strategy based on rivaroxaban (full-dose heparins in unstable patients) + rivaroxaban to day 30 was not better than prophylactic anticoagulation and increased bleeding risk. AND [Preprint] Practice Changing RCT: Therapeutic-dose anticoagulation with heparin (LMWH or unfractionated heparin) improves outcomes in non-critically ill patients with Covid-19 – the superiority of therapeutic-dose anticoagulation was seen in both high and low D-dimer groups. AND [Preprint] RCT: Full-dose/therapeutic anticoagulation provides no benefit in critically ill patients with Covid-19
Commentary on Twitter (thread – click for more)
🚨Final results of the RAPID trial now pub'd @medrxivpreprint 🚨 RAPID was an open-label trial that randomly assigned hospitalized ward patients with COVID-19 and elevated D-dimer levels to therapeutic or prophylactic heparin. 🧵 1/10 https://t.co/oxiyXQAPeK pic.twitter.com/V2GtruEyM2
— Michelle Sholzberg (@sholzberg) July 9, 2021
RCT: Another study shows Azithromycin does not improve outcomes in patients with Covid-19.
12 Jul, 2021 | 03:09h | UTCCommentaries: Trial shows that the antibiotic azithromycin does not prevent mild COVID cases progressing to hospitalization, death – European Society of Clinical Microbiology and Infectious Diseases AND Azithromycin: can its benefit be ruled out in mild COVID-19? – The Lancet Respiratory Medicine
Related: M-A: Azithromycin does not reduce the need for invasive mechanical ventilation or mortality in patients with Covid-19. AND RCT: Azithromycin provides no benefit for community treatment of patients with suspected COVID-19 AND RECOVERY trial: Azithromycin not beneficial for patients admitted to hospital with COVID-19 AND [Press release – not published yet] Azithromycin and doxycycline are not generally effective against COVID-19 in patients treated at home, shows PRINCIPLE trial AND Coalition Covid-19 Brazil – Randomized trial: Azithromycin not beneficial for patients admitted to the hospital with severe Covid-19 AND Coalition Covid-19 Brazil – Randomized trial: hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19
Commentary on Twitter
In patients with mild-to-mod #COVID19 managed without hospital admission, azithromycin + SOC did not reduce the risk of subsequent hospital admission or death
Read the ATOMIC2 trial here https://t.co/QXJ7T08JZS, being presented at #ECCMID2021 by lead author Tim Hinks @HinksLab pic.twitter.com/ZDiPhuQqFB
— The Lancet Respiratory Medicine (@LancetRespirMed) July 9, 2021